Group 1 - The company has successfully won bids for eight major products in the national traditional Chinese medicine procurement alliance, covering treatment areas such as cardiovascular diseases, respiratory diseases, and digestive system diseases, which are commonly used in clinical applications and included in medical insurance and essential drug lists [2] - The successful bidding aligns the products with DRG/DIP payment requirements, providing better medication options for more patients and enhancing future market demand, market coverage, and sales potential for the company's products [2] - The traditional Chinese medicine granule industry is entering a period of deep adjustment characterized by declining sales, with the company's sales revenue for traditional Chinese medicine granules decreasing by 14.4% due to multiple policy impacts [2] Group 2 - For the fiscal year ending December 31, 2025, the company reported a revenue of RMB 3.135 billion, a decrease of 17.0% compared to the previous year, with a gross margin of 72.3%, down from 75.0% last year [3] - The annual profit increased by 13.1% to RMB 950 million, with earnings per share at RMB 1.26, and the company declared an interim dividend of RMB 0.43 per share for 2026 [3]

Summary of the Conference Call for China Traditional Chinese Medicine (CTCM) Company Overview - **Company**: China Traditional Chinese Medicine (CTCM) - **Fiscal Year**: 2025 - **Key Financials**: - Net loss attributable to shareholders: CNY 342 million - Net profit margin: -3.1% - Revenue: CNY 14.745 billion (down 10.7% YoY) - Total assets: CNY 32.347 billion (down 7.7% YoY) - Total liabilities: CNY 9.32 billion (down 16.3% YoY) [2][3][10] Industry Insights - **Market Dynamics**: - The Chinese herbal medicine industry is facing increased competition and pressure from centralized procurement policies. - The market for traditional Chinese medicine (TCM) is undergoing significant changes, with a focus on quality and integration across the supply chain [15][21]. Key Business Segments Performance 1. **Chinese Herbal Medicine Granules**: - Revenue: CNY 6.098 billion (down 12.5% YoY) - Gross margin: 53.8% (down 3.1 percentage points) - Impacted by increased competition and a higher proportion of centralized procurement [2][8]. 2. **Chinese Herbal Pieces**: - Revenue: CNY 3.334 billion (up 0.6% YoY) - Gross margin: 25.1% (up 1.9 percentage points) - Growth attributed to optimized sales structure and reduced procurement costs [2][8]. 3. **Traditional Chinese Medicine (TCM)**: - Revenue: CNY 4.248 billion (down 6.7% YoY) - Gross margin: 66.7% (up 3.1 percentage points) - Growth in prescription drugs and the launch of an e-commerce strategy for OTC products [2][9]. 4. **Health and Wellness Sector**: - Revenue: CNY 235 million (down 17.2% YoY) - Gross margin: 31.9% (up 7.5 percentage points) - Decline due to strategic withdrawal from low-efficiency product lines [9]. Strategic Initiatives - **2026 Strategy**: Focus on "stability, integration, and efficiency" to manage costs and enhance supply chain management [11][12]. - **Supply Chain Management**: Emphasis on strategic reserves of bulk medicinal materials and graded processing to control costs [13]. - **Digital Transformation**: Development of a data platform for full-chain management of TCM production, aiming for enhanced traceability and quality control [14][19]. Research and Development - **Innovation**: - 207 patents granted in 2025, including 126 invention patents. - Participation in drafting 57% of the national standards for herbal granules [6][7]. - **Clinical Research**: Focus on evidence-based medicine to enhance product lifecycle and efficacy [16][17]. Financial Health - **Debt Management**: Debt ratio reduced to 11.8% (down 6.7 percentage points) with cash reserves of CNY 4.045 billion [10]. - **Accounts Receivable**: Increased by 4.6% due to tight healthcare funding, with 50.4% of receivables aged under 90 days [10]. Future Outlook - **Market Conditions**: Anticipated continued pressure on the herbal granules segment due to ongoing centralized procurement policies [21]. - **Growth Expectations**: The company aims for stable revenue and profit in 2026, with a focus on transforming the herbal granules business and strengthening core segments [18][21]. Conclusion CTCM is navigating a challenging environment marked by regulatory changes and competitive pressures. The company is strategically positioned to leverage its R&D capabilities and supply chain management to enhance its market position while focusing on digital transformation and quality improvement initiatives.

Group 1: Product Pricing and Stability - The core products' pricing system remains stable, with no expected price drops for the Wuling series and Bailing series, which are key products in the national medical insurance system [1][2] - The Bailing tablets and capsules have been selected for the national Chinese medicine procurement alliance, with the procurement period lasting until the end of 2027, ensuring price stability during this time [2] Group 2: Sales Channels and Strategies - The sales distribution is approximately 90% from hospital channels and 10% from external channels, with a strategy to deepen hospital penetration and expand external sales [3] - The company aims to leverage its advantages in national basic medicine and procurement selections to enhance coverage in hospitals, particularly in county-level medical communities [3] Group 3: Market Position and Competition - The multi-micro asset group products are covered in over 20 provinces, with a strong market presence in pediatric and maternal-child hospitals, and the brand "Litianwei®" has gained recognition [4] - Wuling capsules hold the top market share in the traditional Chinese medicine neurological field in urban and county public hospitals, with main competitors including Bailemi capsules and Zao Ren An Shen granules [6] Group 4: Organizational Structure - The marketing headquarters includes various departments such as self-operated hospital divisions, OTC business, and government affairs, employing a combined sales model of self-operation and agency [7] Group 5: Industry Environment and Policy Impact - The year 2026 marks the beginning of the "14th Five-Year Plan," with ongoing policy benefits for the traditional Chinese medicine industry, creating structural opportunities in both hospital and external markets [8] - Recent government guidelines aim to enhance grassroots medical services, providing market opportunities for the company to expand its existing four basic medicine varieties [8]

Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Insights - The year 2025 is characterized by the Chinese medicine industry experiencing a bottoming out phase amid multiple pressures, with both performance and valuation reaching historical lows. The industry faces challenges from demand decline, high base effects, and inventory destocking. Policy impacts include centralized procurement and price governance, which disturb market expectations, leading to a downward shift in price levels and accelerated industry differentiation. The market performance shows that valuations are at historical lows, with institutional allocation ratios dropping to a low point. The year 2026 will see several critical validation points, focusing on policy and inventory cycles as core variables [4][5][9] Summary by Sections 1. Industry Performance in 2025 - The Chinese medicine industry is expected to face a downturn in 2025, with performance under pressure from demand decline, high base effects, and inventory issues. The industry’s revenue for the first three quarters of 2025 is reported at CNY 259.07 billion, a year-on-year decrease of 4.08%, while net profit is CNY 29.499 billion, down 1.46% [15][16][18] 2. Policy Variables - The year 2026 will see significant policy impacts on the Chinese medicine industry, focusing on four dimensions: top-level design for high-quality development, supply-side optimization, normalization of centralized procurement, and adjustments to the essential drug catalog. The release of the "Implementation Plan for High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)" marks a shift from scale expansion to quality and efficiency improvement, which is expected to enhance the overall competitiveness and sustainability of the industry [5][6][9] 3. Inventory Cycle - After a deep adjustment in 2024-2025, the inventory turnover levels in the Chinese medicine industry are expected to improve gradually. The retail environment is showing signs of recovery, and the adjustment of the essential drug catalog may bring additional demand from hospital channels. The industry is anticipated to gradually clear inventory in 2026, with companies that have high inventory turnover rates and strong brand power likely to recover first [8][9] 4. Investment Strategy - The investment strategy for 2026 emphasizes seeking certainty in alpha through structural differentiation based on core competitiveness. The report recommends focusing on companies with evidence-based medicine, R&D innovation capabilities, quality control advantages, and brand moats. In the hospital market, attention should be paid to the catalytic effects of the essential drug catalog and innovation-driven breakthroughs, while in the external market, recovery driven by inventory stabilization and domestic demand should be monitored [9][10]

Core Viewpoint - The Chinese medicine ETF (560080) has shown positive performance with most constituent stocks rising, indicating a favorable market sentiment towards the Chinese medicine sector [1][6]. Group 1: Stock Performance - Major stocks in the Chinese medicine ETF have seen significant gains, with Da Ren Tang rising over 4%, Pian Zai Huang over 3%, and Tong Ren Tang over 2% [1]. - The estimated weights and performance of key stocks include: - Yunnan Baiyao at 10.56% with a 1.47% increase - Pian Zai Huang at 9.21% with a 3.78% increase - Dong E E Jiao at 6.18% with a 0.73% increase [2]. Group 2: Technological Advancements - The launch of the first "Traditional Chinese Medicine Brain-Machine Interface" equipment marks a significant technological advancement, aimed at treating neurological disorders [3]. - This technology integrates brain-machine interface with acupuncture, showcasing innovation in the field of traditional medicine [3]. Group 3: Policy Developments - The implementation of the "Drug Administration Law Implementation Regulations" emphasizes a review system for traditional Chinese medicine based on traditional theories, human experience, and clinical data [4]. - The regulations aim to ensure the safety and traceability of traditional Chinese medicine products, which may lead to industry consolidation and growth for leading companies [4]. Group 4: Investment Opportunities - Three main investment themes in the Chinese medicine sector are identified: 1. Price governance, focusing on competitive products and companies that can leverage price reductions for volume growth [5]. 2. Consumption recovery, driven by macroeconomic improvement and an aging population, benefiting companies with strong brand and product advantages [7]. 3. State-owned enterprise reform, which may enhance performance through efficiency improvements in state-controlled companies [8]. Group 5: Market Activity - The Chinese medicine ETF (560080) has seen increased trading activity, with a transaction volume nearing 1 billion yuan and significant capital inflow over recent days [6].

Core Viewpoint - The A-share pharmaceutical sector has gained renewed investor interest due to the resurgence of COVID-19 cases in India, leading to fluctuations in the Chinese medicine ETF (560080) and notable stock performance among key companies in the sector [1][6]. Group 1: Market Performance - The Chinese medicine ETF (560080) experienced a nearly 2% decline on January 27, following a more than 1.4% increase the previous day, with trading volume surpassing 85 million yuan [1]. - Notable declines were observed in key stocks within the ETF, including Zhongsheng Pharmaceutical down over 7% and Yiling Pharmaceutical down over 5%, with several others also experiencing declines [3]. Group 2: Valuation Insights - The latest price-to-earnings ratio (PE TTM) for the index tracked by the Chinese medicine ETF (560080) is 24.57, indicating that the valuation is below 81.27% of the time since the index was published in May 2015, suggesting a favorable valuation opportunity [4]. Group 3: Company News - Zhongsheng Pharmaceutical announced a projected net profit of 260 million to 310 million yuan for 2025, marking a significant turnaround with an increase of 186.91% to 203.62% year-on-year [7]. - Yiling Pharmaceutical also forecasted a net profit of 1.2 billion to 1.3 billion yuan for 2025, indicating a key operational turning point [7]. - Kangyuan Pharmaceutical received approval for clinical trials of a new traditional Chinese medicine aimed at treating children's adenoid hypertrophy, marking a step forward in innovation [7]. Group 4: Industry Trends - The Chinese traditional medicine market is projected to exceed 700 billion yuan in 2024, driven by stable demand amid an aging population, although pricing volatility has been influenced by inventory adjustments and procurement policies [8]. - The industry is experiencing a consolidation trend, with leading companies capturing over half of the market revenue and profits, while ongoing policy focus on innovation and quality development is reshaping the competitive landscape [8].

Investment Rating - The report indicates a cautious investment outlook for the Chinese traditional Chinese medicine (TCM) industry, highlighting short-term pressures and long-term quality improvement opportunities [2]. Core Insights - The TCM industry is experiencing stable demand due to an aging population, with the market size expected to exceed 700 billion yuan by 2024, reflecting a year-on-year growth of approximately 6.6% [4][11]. - The financial performance of TCM listed companies is under pressure, with high sales expenses eroding profits and increasing internal differentiation among companies [11][25]. - The competitive landscape is characterized by a high concentration of revenue and profits among the top tier of companies, which hold over half of the industry's income and profits due to proprietary formulas and brand advantages [20][22]. Industry Overview - The TCM industry has a well-established supply chain, with stable demand driven by an increasing elderly population, projected to reach 220 million by the end of 2024, a 1.36% increase from 2023 [4]. - The industry is facing significant price fluctuations due to inventory destocking, upstream capacity changes, and downstream procurement policies [4][5]. - The TCM manufacturing sector consists of approximately 5,000 companies, primarily located in regions such as Jilin, Guangdong, Anhui, and Henan [4]. Financial Performance of TCM Companies - As of 2024, there are 70 listed TCM manufacturing companies, with an average annual revenue of about 340 billion yuan and an average profit of around 34 billion yuan [11][13]. - The overall profit margin for TCM companies is below 20%, indicating a challenging financial environment [11]. - The sales gross margin for sample companies remains stable at around 55%, while the sales expense ratio is approximately 24% [14][18]. Competitive Landscape - The first tier of TCM companies, including Yunnan Baiyao and Tongrentang, dominate the market, accounting for over 52% of total revenue and profits [22][25]. - The second tier includes regional leaders with a more diverse product range, while the third tier consists of smaller companies with concentrated product lines [23][24]. - The financial data shows that the first tier companies have significantly higher equity scales, providing a solid foundation for market expansion and R&D [26]. Industry Policies - Recent policies emphasize innovation and quality improvement in the TCM sector, with initiatives aimed at enhancing regulatory frameworks and promoting high-quality development [27][28]. - The government has outlined plans to establish national laboratories and improve the quality of TCM products through stricter regulations [28][29]. TCM Procurement Situation - The gradual implementation of TCM procurement policies has led to significant price reductions, with the average price drop reaching 68% in recent rounds of procurement [31][34]. - The procurement process is designed to promote standardization and quality control, which may lead to increased market concentration among leading companies [31][40]. - The report notes that the procurement policies have created challenges for TCM companies, particularly regarding profitability due to cost pressures [40]. TCM Innovation Drug Development - The TCM sector has seen a surge in innovation, with a notable increase in clinical trial applications and new drug approvals, particularly in areas such as digestion and respiratory health [41][42]. - The number of IND applications for TCM has grown significantly, indicating a robust pipeline for future product development [42][43].

Macro Strategy - Recent international gold prices are fluctuating at high levels, with domestic jewelry gold prices also remaining elevated. There is a new trend in gold consumption favoring lighter products like gold bars. Short-term gold prices are expected to maintain high volatility. Consumers should pay attention to international gold price fluctuations if investing, and choose purchasing timing based on their budget for wearing needs [2][3] - From January to October, the national general public budget revenue reached 18.649 trillion yuan, a year-on-year increase of 0.8%. The national general public budget expenditure was 22.5825 trillion yuan, a year-on-year increase of 2%. Securities transaction stamp duty revenue was 162.9 billion yuan, a year-on-year increase of 88.1% [2] - By the end of 2024, the total asset scale of urban commercial banks in China is projected to be 60.15 trillion yuan, a 134-fold increase since 1995, accounting for 13.53% of the banking financial institutions, with a market share increase of 8.24 percentage points. The non-performing loan ratio is 1.76%, and the provision coverage ratio is 188.08% [2] Industry and Company Medical Services Industry - The medical and biological sector rose by 3.29%, ranking fifth among the 31 first-level industries. The Shanghai and Shenzhen 300 Index fell by 1.08%, indicating that the medical sector outperformed the index by 4.37 percentage points [6] - The PE (ttm) of the medical services sector is 33.47X, with a PB (lf) of 3.37X. The PE increased by 0.51X and the PB increased by 0.05X compared to the previous week [7][8] - The TIDES CRDMO market is expected to grow significantly, with the global market projected to increase from 2.1 billion USD in 2018 to 5.5 billion USD in 2023, with a CAGR of 20.9%, and further to 37.3 billion USD by 2032, with a CAGR of 23.8%. The Chinese market is expected to grow from 200 million USD in 2018 to 800 million USD in 2023, with a CAGR of 37.1%, and to 6.2 billion USD by 2032, with a CAGR of 25.5% [9] - Investment recommendations for the medical services sector include focusing on high-growth companies in the ADC CDMO and TIDES CDMO areas, as well as companies in the third-party testing laboratories and consumer medical sectors [10] Traditional Chinese Medicine Industry - The traditional Chinese medicine sector rose by 4.08%, ranking third among secondary sub-sectors. Companies such as Te Yi Pharmaceutical and Zhongsheng Pharmaceutical performed well, while others like *ST Changyao and ST Huluwa performed poorly [12] - The PE (ttm) for the traditional Chinese medicine sector is 29.25X, with a PB (lf) of 2.47X, indicating a slight increase from the previous week [13][14] - The market for traditional Chinese medicinal materials is experiencing volatility, with an overall supply surplus due to increased arrivals from new harvests. Recent weather conditions have also impacted harvesting [15] - The steady advancement of centralized procurement in the traditional Chinese medicine industry aims to reduce patient medication costs and shift competition towards cost control and quality standards [16][17] - Investment recommendations for the traditional Chinese medicine sector include focusing on companies with competitive advantages in product quality and cost, as well as those benefiting from national reforms and centralized procurement policies [18][19]

Investment Rating - The industry rating is maintained at "Overweight" [6] Core Views - The Chinese medicine industry is experiencing steady progress in centralized procurement, with a focus on companies that have advantages in product variety, quality, and cost [5][9] - The market performance of the Chinese medicine sector has shown a 4.08% increase recently, ranking third among secondary sub-sectors [2][13] - The price governance policies are expected to lead to a clearer differentiation within the industry, benefiting companies with competitive advantages [10][11] Market Performance - The Chinese medicine sector's PE (ttm) is 29.25X, which has increased by 1.14X week-on-week, while the PB (lf) is 2.47X, up by 0.1X [3] - The overall market for Chinese medicinal materials is experiencing volatility, with a recent price index of 225.47 points, down 0.2% from the previous week [4] Centralized Procurement - The fourth batch of centralized procurement for traditional Chinese medicine has been initiated, with significant competition in certain product groups [5] - The "3+N" alliance in the Beijing-Tianjin-Hebei region has also started procurement for 200 types of Chinese medicine formula granules [5] Investment Suggestions - Focus on three main lines: price governance, consumption recovery, and state-owned enterprise reform [10][11] - Recommended companies include Zhaoli Pharmaceutical and Yiling Pharmaceutical, with a watch on Pizaihuang and Shouxiangu [11]

Core Viewpoint - The company is focusing on its main business while expanding its product offerings in traditional Chinese medicine, particularly in the herbal medicine segment [1] Group 1: Company Strategy - The company is actively selling its main products, including Yuanhu Zhitong Diban and Xuanfei Zhiso Heji, while also developing its herbal medicine business [1] - The company has not yet participated in centralized procurement for its herbal medicine products and is monitoring related policies and market dynamics [1] Group 2: Market Positioning - The company aims to align its herbal medicine business with market demand and its strategic planning to create value for itself and its shareholders [1]